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Abstract: Consecutive treatment of adult rat heart with isoproterenol and adenosine (Iso/Aden),
known to consecutively activate PKA/PKC signaling, is cardioprotective against ischemia
and reperfusion (I/R). Whether this is cardioprotective in an immature heart is unknown.
Langendorff–perfused hearts from adult and immature (60 and 14 days old) male Wistar rats were
exposed to 30 min ischemia and 120 min reperfusion, with or without prior perfusion with 5 nM
Iso for 3 min followed by 30 µM Aden for 5 min. Changes in hemodynamics (developed pressure
and coronary flow) and cardiac injury (Lactate Dehydrogenase (LDH) release and infarct size) were
measured. Additional hearts were used to measure glycogen content. Iso induced a similar inotropic
response in both age groups. Treatment with Iso/Aden resulted in a significant reduction in time to
the onset of ischemic contracture in both age groups whilst time to peak contracture was significantly
shorter only in immature hearts. Upon reperfusion, the intervention reduced cardiac injury and
functional impairment in adults with no protection of immature heart. Immature hearts have
significantly less glycogen content compared to adult. This work shows that Iso/Aden perfusion
confers protection in an adult heart but not in an immature heart. It is likely that metabolic differences
including glycogen content contribute to this difference.
Keywords: ischemia; isoproterenol; adenosine; cAMP; immature heart; cardioprotection; glycogen
1. Introduction
Cardiac ischemia and reperfusion (I/R) injury is an important factor that contributes to
morbidity and mortality during open heart surgery [1,2]. Therefore, the search continues for
potent cardioprotective interventions that can be used to protect the adult and pediatric heart.
We relatively recently described cardioprotective intervention termed temperature preconditioning
(TP) [3] that confers protection by increasing myocardial cAMP and subsequent activation of Protein
Kinase A (PKA) followed by activation of Protein Kinase C (PKC) [4]. This sequence of events
was confirmed by our finding that the PKA inhibitor H-89 attenuated PKC activation following
TP [4,5] and led us to the formulation of a new cardioprotective pharmacological strategy that
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involves cAMP/PKA/PKC signaling. Based on this strategy, we have found that the normal adult
rat heart can be effectively protected against I/R injury by transient and consecutive treatment
with clinically relevant doses of isoproterenol and adenosine (Iso/Aden) [6]. This intervention has
also been shown to protect hearts when applied during hypothermic cardioplegic arrest [7] and
in rat models of heart failure and aging [6,8]. Interestingly, this treatment results in a decrease in
glycogen content in the myocardium [4,6]. Glycogen breakdown and subsequent accumulation of
glucose-6-phosphate and low pH during ischemia triggers dissociation of mitochondrial hexokinase
2 which can reduce mitochondrial permeability transition pore (MPTP) opening and cardiomyocyte
death [9–11]. What is not known is whether this intervention can protect the immature heart. This
issue is further complicated by the fact that unlike adult heart, the vulnerability of postnatal hearts to
I/R changes during development and follows a triphasic pattern in rats with 1 and 14–21 days old
being most resistant to I/R injury [12–15]. Clinical research has also shown developmentally-related
differences in cardiac vulnerability to cardiac I/R in patients undergoing open heart surgery [16,17].
The underlying mechanisms are not known but may include developmental changes in caloric
intake/body mass [15,18] and in Ca2+ mobilization. This metabolic link could also involve cAMP/PKA
signaling pathway, which is important in the regulation of cardiac Ca2+ cycling. In fact, cell cycle arrest
of cardiomyocytes in G1 phase could involve β-adrenergic receptors (β-AR) [19]. The aim of this work
was to investigate whether an immature heart of 14 days postnatal age (selected to have relatively high
resistance to I/R) can also be protected by Iso/Aden treatment.
2. Results
2.1. Effect of Isoproterenol on Cardiac Function in Adult and Immature Heart
The coronary flow rate (CFR) (Figure 1) was significantly increased in both groups following
administration of 5 nM isoproterenol. In the adult group, the CFR increased from an average value of
7.7 ± 0.6 mL/min after equilibration to 11.7 ± 1.11 mL/min; the immature group showed an increase
from 3.6 ± 0.26 mL/min to 4.8 ± 0.57 mL/min after Iso perfusion. The percentage increase was similar
for both groups and there was no significant (intergroup) difference in the percentage increase (151.9%
vs. baseline in the adult and 140.2% in the immature animals).
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Figure 1. Maximal change in coronary flow measured in adult and immature hearts prior to (pre-) 
and following (post-) perfusion with 5 nM isoproterenol for 3 min. (Left) panel—absolute changes, 
(Right) panel—proportionate changes relative to control for each age group. Data points are mean ± 
SEM. * p < 0.05 vs. corresponding pre-values. 
Figure 1. Maximal change in coronary flow measured in adult and immature hearts prior to (pre-) and
following (post-) perfusion with 5 nM isoproterenol for 3 min. (Left) panel—absolute changes, (Right)
panel—pro ortionate changes relative to control for each age group. Data points are mean ± SEM.
* p < 0.05 vs. corresponding pre-values.
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There was a significant increase in Left Ventricular Developed Pressure (LVDP, Figure 2) in
both the adult (from 50.00 ± 3.88 to 87.22 ± 9.2 mmHg) and immature hearts (from 32.44 ± 3.99 to
55.88 ± 11.5 mmHg). However, there was no difference between the groups in the percentage increase
in LVDP (174% vs. 172% for adult and immature, respectively).
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2.2. Effects of Isoproterenol/Adenosine Pre-Treatment on Ischemic Contracture 
A representative trace of a single experiment, and mean LVDP during the time following 
reperfusion, are shown in Figures 3 and 4. Figure 3, the trace from a single perfusion experiment, 
shows the typical pattern for an ischemic heart; that is, an LVEDP measurement which falls sharply 
on cessation of coronary flow, but over time during ischemia comes to a peak. This peak is known as 
ischemic hypercontracture. 
Figure 2. Maximal change in left ventricular developed pressure measured (LVDP) in adult and
immature hearts perfused with 5 nM isoproterenol for 3 min. (Left) panel; LVDP prior to heart
perfusion with isoproterenol (Pre-) and at peak of LVDP following addition of isoproterenol (Post-).
(Right) panel; proportionate changes of LVDP during heart perfusion with isoproterenol relative to
control for each age group. Data points are mean ± SEM of mean. * p < 0.05 vs. corresponding
pre- values.
2.2. Effects of Isoproterenol/Adenosine Pre-Treatment on Ischemic Contracture
A representative trace of a single experiment, and mean LVDP during the time following
reperfusion, are shown in Figures 3 and 4. Figure 3, the trace from a single perfusion experiment,
shows the typical pattern for an ischemic heart; that is, an LVEDP measurement which falls sharply
on cessation of coronary flow, but over time during ischemia comes to a peak. This peak is known as
ischemic hypercontracture.
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Figure 3. A representative experimental trace of changes in LV pressure (mmHg) measured before interventions (A), during Isoproterenol (B) and Adenosine (C) and
during Ischemia and early reperfusion. Arrowhead shows the gradual increase in developed pressure that is a measure of ischemic contracture (rigor). Y-axis shows
the developed pressure in mmHg and X-axis shows time in minutes. Scales are shown on the right-hand side of the trace.
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Figure 4. Time course of mean LVDP prior to and following reperfusion measured at 5 min
intervals. Plotted as mean pressure ± SEM. (Top) panel—adult hearts; (lower) panel—14-day old
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Table 1 sho s a su ary of the changes in end diastolic pressure (LVEDP) during ische ia for
both adult and i ature heart. In both age groups, the ti e to onset of ische ic contracture as
significantly shorter in hearts pre-treated ith Iso/Aden. The peak rise in LVEDP as t o-fold lo er
(Table 1) in the drug-treated adult heart co pared to control adult heart and by 40 lo er in the
treated i ature group of hearts. change as also seen in the ti e to peak ische ic contracture,
ith the intervention in the i ature group more than halving this duration. Similarly, the increase in
LVEDP after 30 min of ischemia (Table 1) was twice as high in adult control vs. adult treated heart; in
the im ature group, a similar pattern was observed.
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Table 1. Time to key milestones during experimental protocol. Data presented as mean ± SEM.
Age Group Intervention
Time to Onset of
Ischemic Contracture
(Seconds)
Time to Peak
Ischemic Contracture
(Seconds)
Maximal Increase in
LVEDP during
Ischemia (mmHg)
Increase in LVEDP at
the End of Ischemia
(mmHg)
Maximal Increase in
LVEDP during
Reperfusion (mmHg)
Adult
Control 875 ± 32 1125 ± 18 59.41 ± 6.28 41.33 ± 4.66 66.58 ± 8.42
Iso/Aden 524 * ± 79 1263 ± 69 * 39.21 ± 9.13 * 20.14 ± 5.38 * 33.41 ± 6.59 *
Immature
Control 505 ± 42 † 1312 ± 180 17.56 ± 3.49 † 4.23 ± 1.32 † 14.05 ± 4.17 †
Iso/Aden 296 ± 43 *,† 512 ± 38 (39%) *,† 19.44 ± 8.59 † −12.00 ± 1.17 *,† 8.48 ± 1.86 †
* significant change (p < 0.05) within selected age group, † p < 0.05 vs. The adult group.
2.3. Effects of Isoproterenol/Adenosine Pre-Treatment on Outcome Following Reperfusion
2.3.1. Developed Pressure Following Ischemia and Reperfusion (I/R) Injury in
Adults & Immature Hearts
Figure 5 shows LVDP in adult and immature hearts exposed to I/R, with and without intervention,
measured, at 30 min and 2 h following reperfusion. In adult hearts, LVDP was significantly higher in
the Iso/Aden treated group than in the control group at both 30 min (67.3 ± 16.9% vs. 24.4 ± 7.7%)
and 2 h (62.1 ± 18.7% vs. 26.5 ± 15.0%). However, in the immature hearts there was no significant
difference, i.e., no improvement in functional recovery, in the Iso/Aden group compared to control
(at 30 min 38.1 ± 5.3% vs. 24.1 ± 2.3%; at 2 h 27.1 ± 3.2% vs. 22.9 ± 2.9%).
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pre-treated adult hearts compared to control (25,202 vs. 13,783 mU), but was not significantly different
in pre-treated and control immature heart (7365 vs. 6080 mU).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 13 
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Figure 6. The effect of Iso/Aden on LDH release after ische ia/reperfusion. LDH activity vs. time
after reperfusion commenced for intervention (Iso/Aden treatment) and control experiments in the
adult and immature groups. Data normalized to the coronary flow rate during the collection of each
fraction. There was no difference within the immature group whereas there was a significant decrease
in LDH release in treated adult hearts. Time = 0 is from a pre-ischemia fraction. Data shown as Mean
± standard error. * = p < 0.05 vs. Adult Control. † = p < 0.05 vs. immature control, ‡ = p < 0.05 vs.
immature hearts treated with isoproterenol/adenosine.
2.3.3. Infarct Size Following I/R Injury in Adults & Immature Hearts
Pre-treatment with Iso/Aden decreased the area of infarcted myocardial tissue in adult hearts
(Figure 7) from 56 ± 5% to 30 ± 5%. Interestingly, the infarct size was smaller in the control immature
hearts than in the control adult hearts, reflecting the same pattern of vulnerability as with LDH
release. Following pre-treatment there was a small, non-significant, decrease in the immature group
(32.0 ± 7.6% vs. 24.2 ± 4.3%). As the infarct size even in the control group for the immature
animals was relatively small, an additio al intermediate group of 28 day old hearts was also used
(5 control, and 5 Iso/Aden). These hearts di not show a significant difference in infarct size following
pre-treatme t (control 4 .00 ± 5.8% vs. interventions 38.5 ± 3.3%). Intra-group comparison shows
increasing vulnerability to infarction, and increasing protection by Iso/Aden pre-treatment with
increasing age after 14 post-natal days.
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Figure 7. The effect of Iso/Aden on infarct size after 30 min ischemia and 2 h reperfusion. Infarct
size in adult, young adult and immature hearts with or without pre-treatment with Iso/Aden. Data
presented as mean ± standard error. * p < 0.05 vs. Control of the same age group.
2.4. The Effect of Age on Cardiac Glycogen Content
Figure 8 shows glycogen content in 5 age groups: 2 neonatal, immature, young adult and adult.
Neonatal hearts had more glycogen than the other age groups. However, there was a marked decrease
in this parameter by day 14, to ~26% of the neonatal level, before it subsequently increased to 47% of
neonatal levels by 31 days post-natal, and 69% at 59 days.
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following sustained long periods of activation of β-AR, which interestingly, is not seen in cardiac
preparations from the 6 day old rat in contrast to the 15, 25-day old and adult rats [20,21].
3.2. Time of Onset to Ischemic Contracture Is Reduced Following Pre-Treatment with Isoproterenol/Adenosine
The pattern of change in LVEDP during ischemia was similar for both control groups (Table 1).
with the time to onset of ischemic contracture not significantly different in adult and immature control
hearts. As expected, the time to the start of ischemic contracture was significantly shorter in both adult
and immature groups when pre-treated with Iso/Aden.
It has been suggested that ischemic contracture can be triggered by low levels of Mg-ATP [22].
The observation of a reduced time to onset of contracture with this pharmacological treatment is
similar to that reported for ischemic preconditioning [7], which was attributed to loss of glycogen
and faster rate of ATP decline during ischemia in these hearts [3,23,24]. Similarly, earlier reports have
shown that higher glycogen content is associated with later onset of ischemic contracture [3,23,24]. Our
data, showing an earlier onset and decreased glycogen content in immature hearts compared to adult
is consistent with this idea which would seem to indicate lower glycogen content being responsible
for this observation, and is confirmed by our findings on the glycogen content of hearts of these age
groups (Figure 8) and in works of others [25,26]. Below, we discuss the implication of this fact for heart
resistance to I/R injury.
3.3. Pre-Treatment with Isoproterenol/Adenosine Protects Adult but Not Immature Heart after I/R
This study confirms our previous observation [4,6] that pre-treatment of adult rat heart
with transient consecutive administration of clinically relevant concentrations of Iso and Aden is
cardioprotective. However, this intervention did not protect immature hearts exposed to a similar
cardiac insult despite both age groups showing similar inotropic responses to Iso perfusion. One major
difference between the adult and immature heart is the higher resistance of the immature heart to I/R
(Figure 7 and see Introduction). It can be argued therefore that since the same ischemic duration was
associated with relatively lower reperfusion injury in the immature heart, which may have masked
any protection. However, even at 28 days (Figure 7), when the control group has a larger infarct size
than immature, Iso/Aden still did not confer significant protection against I/R.
The observed findings of this study can be explained, at least in part, by consecutive activation of
PKA and PKC (protein kinases known to be affected by Iso and Aden) and their respective downstream
proteins. Indeed, cyclic AMP-induced PKA activation has been implicated in the cardioprotective effect
of ischemic preconditioning [27,28]. In our experiments, glycogen depletion could partially explain
the cardioprotective effect in Iso/Aden-treated adult hearts. During ischemia, anaerobic glycolysis
and glycogenolysis are activated leading to acidosis and accumulation of glucose-6-phosphate (G6P)
in myocardium. Hence, the reduced level of glycogen would lead to less acidosis and reduced
G6P accumulation, as it happens during ischemic preconditioning [11], stimulating the binding of
hexokinase II (HKII) to mitochondria and inhibiting the MPTP (mitochondrial permeability transition
pore). In contrast, in control hearts, elevated level of G6P and low pH during ischaemia would lead
to dissociation of HKII from mitochondria [11] and consequently, opening of the MPTP. This causes
irreversible reperfusion damage to myocardium ([29] and see Introduction).
3.4. Low Glycogen Content in Immature Heart Could Blunt Cardioprotection with Isoproterenol/Adenosine
Unlike adult hearts, the immature heart has a lower level of glycogen content which is depleted
relatively quickly during index ischemia as seen by onset of ischemic contracture. More importantly is
the finding that peak ischemic contracture was reached in a very short period of time compared to
control or adult hearts. Thus, it is likely that Iso/Aden pre-treatment, by depleting the relatively lower
levels of glycogen at an early stage during index ischemia, blunted any expected potential benefits
from this intervention, probably due to a significant dysfunction of ATP-dependent ion channels [30].
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Although the role of HKII association and dissociation to mitochondria and the link to glycogen
content has been addressed, little is known about this in immature hearts.
4. Materials and Methods
4.1. Animals & Ethical Approval
Male Wistar rats were used for all experiments. For experiments involving adult rats (control
n = 8, Iso/Aden n = 7), animals of approximately 60 days of age were used; these were obtained from
Charles River Laboratories (Margate, Kent, UK). Rat pups aged 14 days of age were obtained from
the University of Bristol Animal Services Unit and used for the “immature” experiments (control
n = 5, Iso/Aden n = 6). Additional age groups were used for assays of glycogen content and included
2 days (n = 3 samples each with 3 pooled hearts per sample), 7 days (n = 3 samples each with 3 pooled
hearts per sample), and n = 6 for14 days, 31 days and for adult. A young adult group aged 28 days
(n = 6 for both a control and an Iso/Aden intervention arm) was also included for assays of cardiac
vulnerability post-hoc. Rats were stunned by concussion and killed by cervical dislocation, and the
heart was rapidly removed.
All housing and experiments were approved by the University of Bristol Animal Welfare Ethical
Review Board (ethical approval number (UIN) UB/15/017 most recently approved 14 April 2016),
and conducted in a manner compliant with the Animals (Scientific Procedures) Act 1986 of the United
Kingdom and consistent with the Guide for the Care and Use of Laboratory Animals (1996, published
by National Academy Press, 2101 Constitution Ave. NW, Washington, DC, USA).
4.2. Heart Perfusion
Once the heart was excised, the aorta was cannulated using a 16G diameter cannula for adult rats,
and 24G for the immature group. Hearts were then retrogradely perfused at 37 ◦C with Krebs–Henseleit
(KH) buffer (composed of 120 mM NaCl, 25 mM NaHCO3, 11 mM glucose, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 1.2 mM CaCl2, and 4.8 mM KCl) equilibrated with 95% oxygen/5% carbon dioxide using a
Langendorff system (AD Instruments, Sydney, Australia). A Powerlab system with Chart 5 software for
Windows (AD Instruments, v5.5.6), was used to provide negative feedback control of the perfusion rate.
Two pressure transducers were connected to the perfused heart to measure the hemodynamic
parameters. One measured the coronary perfusion pressure, which was held at 80 mmHg for adults,
and 65 mmHg for immature, by alteration of coronary flow rate. Left ventricular pressure (LVP) was
also monitored, via a pressure transducer connected to a thin plastic balloon inserted into the left
ventricle. Left ventricular developed pressure (LVDP) was calculated as the difference between left
ventricular systolic pressure (LVSP) and left ventricular end diastolic pressure (LVEDP).
4.3. Ischemia/Reperfusion Injury Protocol
Hearts were allowed to equilibrate for 30 min. In the intervention group—the Iso/Aden
group—hearts were perfused with KH containing 5 nM Iso for 3 min followed by 5 min perfusion with
KH containing 30 µM Aden, and then a five-minute washout period. Both groups then were subjected
to 30 min global ischemia followed by 120 min reperfusion. Functional endpoints and cardiac injury
were determined in both control and experimental groups. Hemodynamic activity, such as LVDP
and coronary flow (CF), were monitored throughout the experiment. The pre-ischemic data were
analyzed for the effect of 5 nM Iso perfusion on physiological function, whilst the peri- and post-
ischemic data were also assessed for developed pressure as a measure of cardiac function. Effluent
was collected prior to ischaemia and at five-minute intervals during the first 30 min of reperfusion and
used to measure lactate dehydrogenase activity. At the end of reperfusion, hearts were stained using
triphenyltetrozolium chloride (TTC) to determine the size of infarction as described previously [31];
in which the stained hearts were sliced into six sections, and each slice scanned to produce a digital
image. These images were then analysed using the AlphaEase (Alpha Innotec, Kasendorf, Germany)
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software package to calculate the areas of infarcted and non-infarcted tissue. The ratio of infarcted to
total area of the slice was then calculated.
4.4. Glycogen Assays
Glycogen levels were measured by a modified method described by Bergmeyer [32]. In addition to
adult and immature rats, other age groups were included to investigate neonates (2–7 days), immature
(8–22 days) and young adult hearts (4 weeks) [33].
Hearts were excised, rinsed in ice cold phosphate buffered saline (PBS) and blotted on filter paper
before freeze clamping using tongs pre-cooled in liquid nitrogen. The frozen hearts were ground to
a fine powder and placed in liquid nitrogen. 100 mg of tissue was mixed with 0.2 mL of 30% KOH
in a microfuge tube until it dissolved before placing on a heating block at 105 ◦C for 1 h. The sample
was then cooled to 0 ◦C on ice prior to addition of 0.1 mL of 2% Na2SO4 followed by 100% ethanol
(to give a final concentration of 75%) and left at 4 ◦C for 24 h. The resuspension was centrifuged on
a benchtop Eppendorf Centrifuge 5415D at 16,000× g for 2 min, the supernatant discarded and the
pellet resuspended in 1 mL of 80% ethanol. The tube was spun again as before and the supernatant
was discarded. The pellet was allowed to dry out on a heating block at 40 ◦C for 24 h. 0.25 mL of
1 M sodium acetate/1 M acetic acid buffer was added with 0.1 mL of 500 µg/mL amyloglucosidase
(11.5 units/mL, made in the sodium acetate/acetic acid buffer) followed by 0.75 mL H2O. The pellet
was resuspended and the tubes incubated at 37 ◦C for 1 h. 0.2 mL H2O was then added and the
sample spun as before. The supernatant was assayed spectrophotometrically at 450 nm using a glucose
assay kit (Sigma Diagnostic Kit No. 510/510-A, Sigma Aldrich, Darmstadt, Germany). Results were
expressed as µmol glycosyl units/g dry weight. For neonatal and immature rats, 3–10 rats were used
according to the eventual tissue required, and the hearts pooled to get a good yield.
4.5. Statistics
Following export of the data from the packages initially used to capture results, the data were
first processed in Microsoft Excel (Seattle, WA, USA) and subsequent analysis performed with SPSS
Statistics (Version 23, IBM Corporation, New York, NY, USA). Functional analysis was performed using
a paired two-tailed Student’s t-test. Other analysis was performed using unpaired two-tailed Student’s
t-test for hypothesis testing. In all cases, differences were considered significant where p < 0.05. Data
analysis for glycogen assays was performed by 1-way ANOVA, and post-hoc analysis performed by
Bonferroni’s correction.
5. Conclusions
This work shows that unlike the adult heart, the immature heart is not protected by pre-treatment
with consecutive Iso/Aden. Relatively lower glycogen content in the immature heart may be
responsible for this effect. However, to establish a definitive causal relationship, further study
is needed. Such a study would examine changes in glycogen levels caused by isoproterenol and
adenosine pre-treatment, as well as the influence of glycogen content on reperfusion injury in hearts
from other postnatal age groups.
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